CloneID: Sch 55700 (Reslizumab)
Antigen Long Description: The parental rat antibody 39D10 was generated by immunizing a male lewis rat with semi-purified recombinant mammalian-expressed IL-5. The original Sch 55700 antibody was generated by grafting CDRs of the original rat antibody on to human framework regions.
Buffer Composition: PBS only.
Uniprot Accession No.: P05113
Specificity Statement: This antibody recognizes and binds human interleukin-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. This antibody specifically recognizes amino acids 89–93 (ERRRV) of human IL-5 and is capable of blocking the binding of IL-5 with IL-5 receptor (PMID: 10590259).
Application Notes (Clone): This antibody is a humanized version of anti-IL5 rat antibody 39D10. The binding affinity of the original human IgG4 version of this antibody was measured using Biacore analysis and it was reported that this antibody bound human IL-5 with a Kd= 81pM (PMID: 7613159). This antibody was capable of inhibiting the binding of hIL-5 to Ba/F3 cells and IL5 induced proliferation of human erythroleukemic cell line TF-1 with an EC50 of 45pM. The in vivo activity of this antibody was studied in Ascaris responsive monkeys, and it was reported that this antibody inhibits eosinophilia in allergic animal models with an extended biological duration (PMID: 7613159). This antibody was active against lung eosinophilia in allergic monkeys and mice and against pulmonary eosinophilia and airway hyperresponsiveness in allergic guinea pigs. It was reported that this antibody did not cause immunosuppression in guinea pigs (PMID: 9698918). It also blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs. In allergic rabbits, this antibody blocks cutaneous eosinophilia. In allergic cynomolgus monkeys, a single dose of this antibody (0.3 mg/kg i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months (PMID: 10514907). A study was also conducted to determine the effect of this antibody in patients with severe persistent asthma (PMID: 12649124). Clinical trials were conducted with this antibody to reduce asthma exacerbations, control asthma-related symptoms and improve pulmonary function in patients with eosinophilic asthma (PMID: 26372797).
English
Deutsch
